Dechloroethylation of ifosfamide and neurotoxicity.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  The Lancet

• Publication date

  1986-11-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0140-6736(86)92227-0PMID 2877353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma

  2004cited by this paper
• Avoiding ifosfamide/mesna encephalopathy.

  1986cited by this paper
• Prediction of ifosfamide/mesna associated encephalopathy.

  1986cited by this paper
• Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.

  1986cited by this paper
• Ifosfamide/mesa and encephalopathy.

  1985cited by this paper
• Encephalopathy associated with ifosphamide/mesna therapy.

  1985cited by this paper
• IFOSFAMIDE/MESNA AND ENCEPHALOPATHY

  1985cited by this paper
• Ifosfamide--pharmacology, safety and therapeutic potential.

  1985cited by this paper
• Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.

  1983cited by this paper
• 2-Chloroacetaldehyde, a metabolite of cyclophosphamide in the rat.

  1983cited by this paper
• 2-Chloroacetaldehyde: a metabolite of cyclophosphamide in the rat.

  1983cited by this paper
• Studies on the metabolism of isopnosphamide (NSC-109724) in man.

  1976cited by this paper
• Metabolism of cyclophosphamide by sheep.

  1972cited by this paper

• New metabolic insights into the mechanism of ifosfamide encephalopathy.

  2024cites this paper
• Cytochrome P450 and UDP-Glucuronosyltransferase Expressions, Activities, and Induction Abilities in 3D-Cultured Human Renal Proximal Tubule Epithelial Cells

  2024cites this paper
• Ifosfamide - History, efficacy, toxicity and encephalopathy.

  2023cites this paper
• Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.

  2023cites this paper
• Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

  2023cites this paper
• Encephalopathy Associated with Ifosfamide Use in the Treatment of Patient with Diffuse Large B Cell Lymphoma

  2021cites this paper
• Ifosfamide-induced encephalopathy: about 15 cases and review of the literature

  2020cites this paper
• Ifosfamide induced encephalopathy in a child with osteosarcoma

  2020cites this paper
• Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects

  2020cites this paper
• Ifosfamide‐induced encephalopathy: Brand‐name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®)

  2019cites this paper
• Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population.

  2019cites this paper
• Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde’s contribution to urothelial dysfunction in vitro

  2019cites this paper
• Analysis of the clinical characteristics of pediatric patients who experience ifosfamide‐induced encephalopathy

  2019influential citation
• Methods of Timely Nephrotoxicity Detection in Treatment with Cyclophosphamide

  2018cites this paper
• Comparative Anticancer Activity in Human Tumor Xenograft Models, Preclinical Pharmacology and Toxicology for 4- Hydroperoxyifosfamide (HOOI): A Potential Neuro-Alkylating Agent for Primary and Metastatic Cancers Involving the Central Nervous System

  2017influential citation
• Synthèse et évaluation pharmacologique d’analogues préactivés de l’ifosfamide : prodrogues et nanoparticules à visée antitumorale

  2017influential citation
• Landscape analysis of drugs available for brain tumors

  2017cites this paper
• Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats

  2017cites this paper
• Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion

  2016cites this paper
• La spécialité Ifosfamide EG® engendre-t-elle plus d’encéphalopathie que la spécialité Holoxan® ? Étude au CHU de Grenoble

  2016cites this paper
• Cyclophosphamide and ifosfamide: mechanisms of cytotoxic action and consequences for normal bladder function.

  2015influential citation
• Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury

  2014cites this paper
• Chronic Ifosfamide toxicity: kidney pathology and pathophysiology.

  2014cites this paper
• A Rational for Novel Anti-NeuroOncology Drugs

  2013cites this paper
• Investigation of ifosfamide nephrotoxicity induced in a liver–kidney co‐culture biochip

  2013cites this paper
• Chapter 15 A Rational for Novel Anti-NeuroOncology Drugs

  2013cites this paper
• Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report

  2013cites this paper
• The glycine deportation system and its pharmacological consequences.

  2012influential citation
• Evaluation of the mass transfers of caffeine and vitamin B12 in chloroacetaldehyde treated renal barrier model using a microfluidic biochip

  2012cites this paper
• The effect of N-acetylcysteine on the antitumor activity of ifosfamide.

  2011cites this paper
• Effects of chloroacetaldehyde in 2-chloroethanol-induced cardiotoxicity.

  2011cites this paper
• Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors

  2010cites this paper
• Oxazaphosphorines: new therapeutic strategies for an old class of drugs

  2010cites this paper
• Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs

  2010cites this paper
• Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

  2010cites this paper
• Ifosfamide

  2010cites this paper
• Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

  2010cites this paper
• Suppression of plasma glutathione peroxidase activity by ifosfamide.

  2010cites this paper
• Targets of chloroacetaldehyde-induced nephrotoxicity.

  2010cites this paper
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans

  2010cites this paper
• Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF‐7

  2009cites this paper
• DMD # 30973-1-Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice , Rats , Dogs and Humans

  2009cites this paper
• Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS.

  2009cites this paper
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs and Humans

  2009cites this paper
• Chloroacétaldéhyde : de l’implication dans les mécanismes physiopathologiques de la néphrotoxicité de l’ifosfamide à la contribution à son effet anticancéreux

  2009influential citation
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs and Humans

  2009cites this paper
• Encephalopathy after High-Dose Ifosfamide

  2008cites this paper
• Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo

  2008cites this paper
• The effect of route of administration and fractionation of dose on the metabolism of ifosfamide

  2008cites this paper
• Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

  2007cites this paper
• Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma

  2007cites this paper
• Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.

  2007cites this paper
• Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study

  2007cites this paper
• Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde

  2007cites this paper
• Design of new oxazaphosphorine anticancer drugs.

  2007cites this paper
• Les alkylants

  2007cites this paper
• Potentiation of Cytochrome P 450 / Cyclophosphamide-based Cancer Gene Therapy by Coexpression of the P 450 Reductase Gene 1

  2006cites this paper
• Efficacy and Toxicity of Ifosfamide Stereoisomers in an in Vivo Rat Mammary Carcinoma Model 1

  2006cites this paper
• [Ifosfamide induced encephalopathy: 15 observations].

  2006cites this paper
• Ifosfamide‐induced nephrotoxicity : Mechanism and prevention

  2006influential citation
• Mass Balance Studies, with a Focus on Anticancer Drugs

  2006cites this paper
• Twin‐track studies of ifosfamide and mitoxantrone (I‐M) in recurrent high grade non‐hodgkin's lymphoma and hodgkin's disease

  2006cites this paper
• Prevention Ifosfamide-Induced Nephrotoxicity : Mechanism and Updated

  2006influential citation
• Mesna Excretion and Ifosfamide Nephrotoxicity in Children1

  2006cites this paper
• Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy.

  2006cites this paper
• Principles of chemotherapy

  2006cites this paper
• Reversal of resistance to oxazaphosphorines.

  2006cites this paper
• Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.

  2006cites this paper
• Encéphalopathie induite par l'ifosfamide : 15 observations

  2006cites this paper
• Enantioselective metabolism of ifosfamide by the kidney.

  2006cites this paper
• Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

  2006influential citation
• Case of chlorambucil‐induced seizure

  2006cites this paper
• Enantiomer–enantiomer interaction of ifosfamide in the rat

  2006cites this paper
• CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION

  2005cites this paper
• Metabolism and pharmacokinetics of oral and intravenous ifosfamide

  2005cites this paper
• Dosing and side-effects of ifosfamide plus mesna

  2005cites this paper
• L-carnitine: a way to decrease cellular toxicity of ifosfamide?

  2005cites this paper
• Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells

  2005cites this paper
• Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

  2005cites this paper
• Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs.

  2005cites this paper
• Metabolism and Transport of Oxazaphosphorines and the Clinical Implications

  2005cites this paper
• Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study

  2005cites this paper
• Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies

  2004cites this paper
• Cancer chemotherapy and mechanisms of resistance

  2004cites this paper
• Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy

  2004cites this paper
• Chapter 47 – Management of Complications of Chemotherapy

  2004cites this paper
• Ifosfamide in pediatric malignant solid tumors

  2004cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper
• Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy

  2004cites this paper
• Ifosfamide pharmacokinetics

  2004cites this paper
• Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children

  2004influential citation
• Studies into the mechanism of ifosfamide-induced encephalopathy

  2004cites this paper
• Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide

  2004cites this paper
• Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

  2004influential citation
• Influence of Age Upon Ifosfamide‐Induced Nephrotoxicity

  2004cites this paper
• Investigations on the pharmacokinetics of trofosfamide and its metabolites—first report of 4-hydroxy-trofosfamide kinetics in humans

  2004cites this paper
• Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite

  2004cites this paper
• The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion

  2004cites this paper
• Pharmacology of Ifosfamide

  2003cites this paper
• Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods.

  2003cites this paper